Investigation of Genetic Disease Marker Associated With Spontaneous Haemorrhagic Stroke Complicating Severe Pre-eclampsia in Pregnancy

• Sponsor: Asfendiyarov Kazakh National Medical University (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT05121415
• Collaborator: (none)
• Enrollment: 100
• Location: 1
• Anticipated Duration (Months): 13.9
• Patients Per Site Per Month: 7.2

Study Details

Study Description

Brief Summary

To search for a genetic marker of hemorrhagic stroke complicating severe eclampsia, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with hemorrhagic stroke and normal control will be performed.

Condition or Disease	Intervention/Treatment	Phase
Hemorrhagic Stroke; Eclampsia	Genetic: SNP analysis of the DNA

Detailed Description

Detailed Description:

Unrelated Korean subjects who have Spontaneous hemorrhagic stroke complicating severe eclampsia in pregnancy were recruited in the current study. Genotyping for various SNP associated due to the linkage disequilibrium patterns is to be performed. Genotypes would be statistically compared between patients with hemorrhagic stroke and normal control subjects free of hemorrhagic stroke

Study Design

• Study Type: Observational
• Anticipated Enrollment: 100 participants
• Observational Model: Other
• Time Perspective: Prospective
• Official Title: Preventive and Personalized Medicine (2021-2023)
• Actual Study Start Date: Oct 23, 2021
• Anticipated Primary Completion Date: Dec 20, 2021
• Anticipated Study Completion Date: Dec 20, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental group: patients with hemorrhagic stroke complicating severe pre-eclampsia in pregnancy	Genetic: SNP analysis of the DNA; SNP analysis of the DNA obtained from peripheral blood sample
Control group patients without hemorrhagic stroke complicating severe pre-eclampsia in pregnancy	Genetic: SNP analysis of the DNA; SNP analysis of the DNA obtained from peripheral blood sample

Outcome Measures

Primary Outcome Measures

1. genotyping for the SNP associated with hemorrhagic stroke complicating severe eclampsia in pregnancy [1 year]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 45 Years
• Sexes Eligible for Study: Female

Inclusion Criteria:

-patients with hemorrhagic stroke complicating severe eclampsia in pregnancy

Exclusion Criteria:

patients without hemorrhagic stroke complicating severe eclampsia in pregnancy

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Hospital	Almaty		Kazakhstan

Sponsors and Collaborators

• Asfendiyarov Kazakh National Medical University

Investigators

• Study Director: Aygul Terlikbayeva, PhD, JSC "Scientific center of obstetrics, gynecology and perinatology"

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Ildar Fakhradiyev, Head of the Laboratory of Experimental Medicine, Asfendiyarov Kazakh National Medical University
• ClinicalTrials.gov Identifier: NCT05121415
• Other Study ID Numbers: 1189
• First Posted: Nov 16, 2021
• Last Update Posted: Nov 16, 2021
• Last Verified: Nov 1, 2021

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Ildar Fakhradiyev, Head of the Laboratory of Experimental Medicine, Asfendiyarov Kazakh National Medical University: SNP
• Additional relevant MeSH terms: Stroke; Hemorrhagic Stroke; Eclampsia

Study Results

No Results Posted as of Nov 16, 2021